Tirzepatide vs Retatrutide: GIP/GLP-1 vs Triple Agonist Evidence

Tirzepatide and retatrutide are both Eli Lilly molecules, both long-acting peptides dosed once weekly, and both produced the biggest weight-loss numbers of their respective trial cohorts. The mechanistic difference is one receptor: tirzepatide is a dual GLP-1 + GIP receptor agonist (SURMOUNT-1, Jastreboff 2022^[1]), while retatrutide adds glucagon receptor agonism on top of the GLP-1/GIP duo (Jastreboff 2023 phase 2^[4]). That extra receptor is the source of both the upside — an additional energy-expenditure pathway via hepatic and brown-adipose-tissue activation (Sanyal 2024 Nat Med^[5]) — and the downside — a measured 5–7 BPM rise in resting heart rate and a nausea rate running roughly 5–10 percentage points above tirzepatide. This article walks through the receptor pharmacology, the head-to-head magnitude across published trials, the side-effect profile, and what the TRIUMPH phase 3 program will and will not answer.

The honest summary

• Tirzepatide is dual-agonist (GLP-1 + GIP). SURMOUNT-1 (Jastreboff 2022^[1]) produced −20.9% body weight at 72 weeks on the 15 mg arm and −19.5% on the 10 mg arm. SURPASS-2 (Frias 2021^[3]) established tirzepatide as more effective than semaglutide 1 mg in T2D.
• Retatrutide is triple-agonist (GLP-1 + GIP + glucagon). The phase 2 obesity trial (Jastreboff 2023 NEJM^[4]) produced −24.2% body weight at 48 weeks on the 12 mg arm — the largest mean weight loss of any GLP-1-family agent in a published RCT, and at a shorter timepoint than SURMOUNT-1.
• Glucagon agonism adds an energy-expenditure mechanism. The retatrutide MASLD trial (Sanyal 2024 Nat Med^[5]) documented hepatic-fat reduction and a small but measurable bump in resting metabolic rate that tirzepatide does not produce. Mechanistically, glucagon activates BAT and lipolysis; GLP-1 opposes the gluconeogenic side effect that would otherwise raise glucose.
• The trade-off is heart rate and nausea. In Jastreboff 2023^[4], retatrutide raised mean resting heart rate by about 5–7 BPM at the 8–12 mg doses, vs ~3 BPM for tirzepatide in SURMOUNT-1. Nausea ran 23–28% all-grades on retatrutide vs 14–18% on tirzepatide. Both effects are dose-dependent and largest during titration.
• Phase 3 readouts decide it. The TRIUMPH program (obesity, T2D, CV outcomes, OSA, MASH) reads out from 2026 onward; until then, all retatrutide magnitude claims are phase 2 data on a few hundred patients.

Receptor pharmacology: what each agonist actually does

The incretin family acts on three G-protein-coupled receptors with overlapping but distinct downstream effects.

GLP-1 receptor agonism drives the satiety signal: anorexigenic central effects via the hindbrain and hypothalamus, delayed gastric emptying, and glucose-dependent insulin secretion. The semaglutide STEP-1 program (Wilding 2021^[6]) demonstrated GLP-1-monotherapy can deliver −14.9% body weight at week 68. Every modern incretin analog inherits this backbone.

GIP receptor agonism is the part of the tirzepatide story that surprised the field. Native GIP is primarily a postprandial incretin, and historically GIP agonism alone produced little or no weight benefit in animal models. Combined with GLP-1, however, GIP shifts adipocyte biology in a way that potentiates fat loss and may attenuate the nausea signal of pure GLP-1. The pharmacology is still being worked out, but SURPASS-2 (Frias 2021^[3]) established empirically that the dual agonist out-performs semaglutide 1 mg on both HbA1c and weight in T2D.

Glucagon receptor agonism is the retatrutide differentiator. Glucagon raises hepatic gluconeogenesis (bad for diabetes if unopposed), but it also increases resting energy expenditure through hepatic substrate cycling and brown-adipose-tissue activation, and increases lipolysis. The triple-agonist trick is that the GLP-1 component opposes the hyperglycemic effect of glucagon (Jastreboff 2023 showed HbA1c actually fell on retatrutide despite the glucagon arm), leaving the energy-expenditure benefit isolated. Sanyal 2024 Nat Med^[5] reported clinically meaningful liver-fat reductions in MASLD patients, consistent with the hepatic-substrate-cycling mechanism.

Magnitude: head-to-head across the published trials

The cleanest comparison is each agent at its highest published dose against the same outcome (mean percent body-weight change from baseline in adults with obesity without T2D), though the timepoints differ.

• Placebo: roughly −2 to −3% at the 48–72 week endpoints in SURMOUNT-1 and the retatrutide phase 2 (lifestyle counseling only).
• Semaglutide 2.4 mg (Wegovy): −14.9% at week 68 in STEP-1 (Wilding 2021^[6]).
• CagriSema (cagrilintide + semaglutide 2.4 mg): −20.4% at week 68 in REDEFINE-1 (Garvey 2025^[7]); the T2D companion REDEFINE-2 ran lower at −13.7% (Davies 2025^[8]).
• Tirzepatide 10 mg (Zepbound): −19.5% at week 72 in SURMOUNT-1^[1].
• Tirzepatide 15 mg (Zepbound): −20.9% at week 72 in SURMOUNT-1^[1].
• Retatrutide 8 mg: −22.8% at week 48 in Jastreboff 2023^[4] (phase 2; smaller cohort than SURMOUNT-1).
• Retatrutide 12 mg: −24.2% at week 48 in Jastreboff 2023^[4].

Two caveats. First, the retatrutide numbers are phase 2 (338 randomized in the obesity trial) and may attenuate in phase 3 the way most phase-2 magnitudes do; the SURMOUNT trials enrolled 2,000+ each. Second, the timepoint mismatch matters: retatrutide was still on the active titration curve at the 48-week endpoint, and the Jastreboff 2023 trajectory data suggest the 12 mg arm had not plateaued. A like-for-like 72-week retatrutide number is what TRIUMPH-1 will deliver.

Magnitude chart: peer-trial weight loss

Side-effect profile: nausea, heart rate, GI tolerability

The two molecules share the GLP-1 GI tolerability spectrum — nausea, vomiting, diarrhea, constipation — but retatrutide adds a measurable cardiovascular signal.

Nausea: In SURMOUNT-1^[1], all-grade nausea ran 18–33% across the tirzepatide arms with the 5 mg arm at the lower end and the 15 mg arm at the upper end; most events were mild and transient during the titration ladder. In Jastreboff 2023^[4], nausea ran 35–43% across the active retatrutide arms with the 12 mg arm highest. Roughly speaking, retatrutide adds about 10 percentage points of all-grade nausea at peer doses.

Resting heart rate: SURMOUNT-1^[1] reported a mean resting HR increase of about 2–4 BPM on tirzepatide. Jastreboff 2023^[4] reported about 5–7 BPM on retatrutide at 8–12 mg, with a small subset of patients showing larger increases. Mechanistically the difference is consistent with glucagon receptor agonism; clinically the question is whether the increase is benign (as it appears to be in healthy participants enrolled in phase 2) or a concern in patients with established cardiovascular disease. TRIUMPH-3 (obesity + established CVD) is the readout that will resolve it.

Vomiting and diarrhea track nausea, roughly proportional. Injection-site reactions are comparable. Pancreatitis and gallbladder signals across both programs are within the expected GLP-1 range. Suicidality signals have not emerged in either program through published data.

Body composition and energy expenditure

The SURMOUNT-1 DEXA substudy (Look 2025^[2]) reported tirzepatide 10 mg produced −33.9% fat mass and −10.9% lean mass at week 72, with lean mass accounting for about 25% of total weight loss — the same fraction seen in diet-only weight loss. The triple-agonist analog of that substudy in the TRIUMPH program has not yet been published, but the Sanyal 2024 MASLD trial^[5] provided indirect signal: retatrutide produced larger reductions in liver fat than would be expected from weight loss alone, consistent with the hepatic-substrate-cycling mechanism. The plausible body-composition hypothesis is that retatrutide delivers a higher fat-to-lean loss ratio than tirzepatide because the glucagon-driven energy expenditure preferentially mobilizes adipose stores; that is a hypothesis waiting on phase 3 DEXA data, not a finding.

TRIUMPH: what phase 3 will and will not answer

The retatrutide phase 3 program (TRIUMPH) is structured similarly to SURMOUNT for tirzepatide:

• TRIUMPH-1: obesity without T2D. The primary like-for-like comparator to SURMOUNT-1. Powered to confirm phase 2 weight-loss magnitude at 72 weeks.
• TRIUMPH-2: obesity with T2D. The HbA1c dimension where the glucagon arm could plausibly under- or over-perform tirzepatide.
• TRIUMPH-3: obesity with established cardiovascular disease. The trial that decides whether the HR signal is benign or clinically meaningful; the analog of the SELECT trial for semaglutide.
• TRIUMPH-4: obesity with OSA. The analog of SURMOUNT-OSA for tirzepatide.
• TRIUMPH-MASH and TRIUMPH-KIDNEY: specialty indications where the triple-agonist mechanism is predicted to outperform dual agonists on biological grounds.

Readouts are staggered through 2026 and 2027. Until then, every retatrutide weight-loss claim in the popular press rests on the phase 2 numbers and a few hundred patients — not the thousands of patient-years that the SURMOUNT program produced. That gap is the central uncertainty for any patient or prescriber weighing “wait for retatrutide” vs “start tirzepatide now.”

Compounded retatrutide and the gray market

Retatrutide is not FDA-approved and has no legal compounding pathway. The peptide is nevertheless available from research-chemical vendors, often marketed for “research use only” with no pharmacy oversight, no third-party assay, and no published bioequivalence to the Lilly investigational drug used in TRIUMPH. The published dose ladder — 0.5 mg start, 2 / 4 / 8 / 12 mg ladder — was developed in trial with rigorous titration and cardiovascular monitoring; reproducing that protocol with a vendor of unknown purity is a different proposition. The prudent default is to wait for approval.

Practical decision framework

1. If you are starting today and need a medication tomorrow, tirzepatide is the right answer. Approved, available through Zepbound and Mounjaro, covered by many commercial plans, and supported by the largest single-agent obesity dataset published.
2. If you are stalled on tirzepatide at the 15 mg dose and have hit a plateau short of your goal, retatrutide is the most plausible next mechanism in the pipeline. Expected approval timeline runs 2027 (TRIUMPH-1 readout 2026 followed by FDA review).
3. If you have cardiovascular disease or uncontrolled hypertension, the HR signal is the dimension to watch. TRIUMPH-3 will provide the safety picture; until then, the conservative call is to stay on tirzepatide or semaglutide (SELECT-supported for CV benefit) rather than chase phase 2 retatrutide numbers.
4. If you have MASLD/MASH or significant hepatic steatosis, the Sanyal 2024 data^[5] make retatrutide a particularly interesting future option; tirzepatide and semaglutide also reduce liver fat, but the triple-agonist mechanism has a plausible incremental benefit there.
5. If you are considering compounded retatrutide, the safety bar is much higher than the price point suggests. Vendor assay quality, dose accuracy, and the absence of cardiovascular monitoring during titration are the load-bearing concerns. The published 5–7 BPM HR increase is not a number to discover on yourself.

Related research

• Retatrutide TRIUMPH phase 3 update — the latest read on the phase 3 program timeline and published readouts.
• Retatrutide triple-agonist mechanism in depth — the GLP-1/GIP/glucagon pharmacology with primary references.
• Retatrutide side-effect profile — nausea, heart rate, GI tolerability across the phase 2 dataset.
• Mounjaro vs Zepbound switching — the tirzepatide branded options for the patient starting today.
• Non-GLP-1 peptides for fat loss — how the gray-market peptide landscape compares to the regulated pipeline.
• GLP-1 muscle loss prevention protocol — protein and resistance-training protocol relevant to both agents.

Important disclaimer. This article is educational and does not constitute medical advice. Retatrutide is not FDA-approved as of this writing; all published efficacy and safety data reflect phase 2 trials. Compounded retatrutide from research-chemical vendors is not the same product evaluated in TRIUMPH and carries unquantified quality and dosing risk. Patients with cardiovascular disease, uncontrolled hypertension, or significant arrhythmia history should discuss any GLP-1-family agent with their prescriber before starting; the heart-rate signal documented for retatrutide warrants particular caution. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 6 months, or sooner when a TRIUMPH phase 3 readout is published.